🕷️
SetupAI
繁
🔥Stalecollected in 2m

China BD Share Rises, Shift to Quality

China BD Share Rises, Shift to Quality
PostLinkedIn
🔥Read original on 36氪
#ai-pharma#bd-trends#valuation-shift#clinical-datapivotal-bioventure-ai-investmentspivotal-bioventureandbot-medqwenglp-1

💡50% global BD share + Ph3 AI drugs highlight China AI-pharma momentum

⚡ 30-Second TL;DR

What Changed

China BD proportion hits 50% globally, diversifies to autoimm, metabolism, new modalities like siRNA

Why It Matters

Elevates China as BD powerhouse but stresses sustainable valuations, boosting AI clinical data focus.

What To Do Next

Analyze Ph3 AI-designed molecules in CNS/metabolism pipelines like Pivotal's investments.

Who should care:Founders & Product Leaders

Key Points

  • •China BD proportion hits 50% globally, diversifies to autoimm, metabolism, new modalities like siRNA
  • •Caution on aggressive pricing eroding China biotech rep; deals mostly $0.5-2B range
  • •AI pharma hot with Ph3 AI-molecules, but optimizes existing vs revolution; focus CTLA-4, GLP-1 expansions

🧠 Deep Insight

Background and context from public sources — not the original article. 6 sources cited.

🔑 Enhanced Key Takeaways

  • •Chinese biopharma companies originated 46% of all new drug molecules entering human trials in the first half of 2025, up from 17% a decade ago[4].
  • •China leads globally in oncology subfields, responsible for 70% of antibody drug conjugates (ADCs) and 60% of bispecific antibodies in development over the past 2.5 years[4].
  • •In early 2026, average upfront payments for China licensing deals rose 22% over 2025's full-year average, reflecting higher valuations[5].
  • •Over 100 small nucleic acid drug pipelines exist in China as of January 2026, mostly targeting chronic diseases beyond oncology[1].

🔮 Future ImplicationsAI analysis grounded in cited sources

China biotech market reaches USD 218 billion by 2034
IMARC projects growth from USD 133 billion in 2025 at 5.64% CAGR, driven by AI integration, regulatory reforms, and international partnerships[2][3].
Chinese firms capture over 50% of global clinical-stage bispecific antibodies
Evaluate data shows China accounting for 48-51% of clinical projects in bispecifics and ADCs, with continued dominance in molecular engineering[4][5].

⏳ Timeline

2017
China joins International Council for Harmonisation, streamlining global drug development guidelines[4]
2019
Global small nucleic acid drug market at USD 2.7B, siRNA share 6.2%; China begins biotech pivot from generics[1][4]
2024
Small nucleic acid market doubles to USD 5.7B, siRNA share 44.5%; China reaches 20% of global drugs in development and matches 80% of US clinical trials[1][3]
2025
Chinese cross-border siRNA deals total over USD 36B; 46% of new molecules in H1 human trials from China[1][4]
2026-01
Over 100 Chinese small nucleic acid pipelines; average licensing upfronts up 22% vs 2025[1][5]
2026-02
SanegeneBio licenses RNAi drug to Genentech for USD 200M upfront, up to USD 1.5B milestones[1]
🔥Read original article on 36氪
📰

Weekly AI Recap

Read this week's curated digest of top AI events →

👉Related Updates

Same topic

Explore #ai-pharma

Same product

More on pivotal-bioventure-ai-investments

Same source

Latest from 36氪

AI-curated news aggregator. All content rights belong to original publishers.
Original source: 36氪 ↗

This is a summary, not the original. Read the source, or get the weekly briefing.

Weekly AI briefing

One email a week. Unsubscribe anytime.